A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Dabrafenib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
Most Recent Events
- 26 Mar 2018 Planned End Date changed from 4 Aug 2017 to 4 Dec 2017.
- 06 Mar 2018 New trial record